Rallybio Corp
rallybio.comWhat Do They Do?
Develops drug candidates for severe and rare diseases, including an inhibitor for complement-related disorders and an antibody for iron-overload diseases.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and…View ↗
Our team has a track record of success in designing, developing, and securing marketing approval for C5 complement inhibitors, including…View ↗
Hematology ("ASH") for RLYB332, the long-acting version of RLYB331, including favorable PD data, that support RLYB332 as a long-acting…View ↗
How Do They Make Money?
Partners pay for licenses and related know-how, research and development work, and collaboration services. Payments may be upfront, tied to milestones, or based on product sales.
10-K for FY2025, filed Mar 16, 2026The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance…View ↗
$858K
-
10-K for FY2025, filed Mar 16, 2026
$858K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
License
Licensed
10-K for FY2025, filed Mar 16, 2026 |
93% |
License, FY2025
$800K Sources
|
Licensed |
|
Collaboration and license revenue
Licensed
10-K for FY2025, filed Mar 16, 2026 |
100% |
Collaboration and license revenue, FY2025
$858K Sources
|
Licensed |
Who Are Their Customers?
Biopharma collaborators, including AbCellera, work with Rallybio through drug-development alliances; a Recursion subsidiary bought Rallybio’s interest in a preclinical program.
10-K for FY2025, filed Mar 16, 2026
Do Revenues Turn Into Profits?
No. It lost $9M in FY2025.
10-K for FY2025, filed Mar 16, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q3 FY2026, filed Oct 27, 2026
−$2.7MView ↗
- ▼ Now a loss
- vs $16M in Q3 FY2025
-
Jun 1, 2026
Agreed to merge with Avenzo and pursue oncology drug development
If completed, Avenzo would become a wholly owned subsidiary, and the combined company is expected to focus on oncology therapies.
Sources
8-K, filed Jun 1, 2026
On May 31, 2026, Rallybio Corporation, a Delaware corporation (“Rallybio”), entered into an Agreement and Plan of Merger and Reorganization…View ↗
-
May 4, 2026
Candid ended its merger agreement with Rallybio
Rallybio is entitled to a $50,000,000 termination fee.
Sources
8-K, filed May 4, 2026
On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the…View ↗
A narrower drug-development portfolio
The earlier report described candidates across maternal-fetal, complement, hematology and metabolic diseases; the latest centers on complement and iron-overload candidates, after ending its maternal-fetal program and selling its interest in a metabolic program.
10-K for FY2022, filed Mar 6, 2023 10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for…View ↗
Our product candidate is targeting the prevention of fetal and neonatal alloimmune thrombocytopenia ("FNAIT") a potentially…View ↗
Treatment of Disorders Due to Complement DysregulationView ↗
We are a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and…View ↗
In July 2025, we entered into a Membership Interest Purchase Agreement (the “ENPP1 Purchase Agreement”) with Recursion Exscientia Ventures…View ↗
In April 2025, we announced the discontinuation of our RLYB212 program for the prevention of FNAIT based on PK data from the Phase 2…View ↗
Loading...
